Cumulus Neuroscience

October is ADHD Awareness Month. Approximately 129 million children and adolescents between the ages of 5 to 19 years old worldwide are living with #ADHD, and it’s estimated that around 30% do not respond to treatment with methylphenidate (such as Ritalin / Concerta / Equasym / Medikinet). Last October, we announced a research collaboration with the dedicated team at Trinity College Dublin and ADMiRE, Linn Dara CAMHS - the Health Service Executive's first specialist service for children and adolescents with ADHD which is focused on the assessment and management of children living with this condition. In this novel study, participants are using the Cumulus Neuroscience NeuLogiq™ platform at home to collect longitudinal brain and behavioral data. We are grateful to our collaborators and study participants for their commitment to advancing the understanding of how the brain works in young people living with ADHD, with the ultimate goal of enabling the characterization of underlying factors associated with predicting treatment response. #trinitycollege #trinitycollegedublin

Last week, Cumulus Neuroscience attended the Digital Health & AI Innovation Summit (#DHAI2024) in Boston where Alison Buick, PhD, Global Head of Business Development participated in a panel discussion titled “Digital Measures in Clinical Trials: Current Challenges and Opportunities for ROI.” It was inspiring to see digital innovation leaders from across the industry come together to explore ways to collectively advance novel objective measures in clinical studies. Key takeaways: - The industry can’t wait until digital endpoints are accepted by the FDA – there’s value in using them today as exploratory endpoints to complement traditional measures and inform early-stage go/no-go decisions with more precision. - Digital endpoints enable collection of objective repeated measures which can overcome hour-to-hour and day-to-day variability in certain disease states- “Why compromise on snapshots when you can get the whole movie?” ***best quote of the day from Amir Lahav who moderated the session*** - “Just because we can measure something doesn’t mean we should.” Focus on measurements that are important to patients – include patients in the development and validation of digital endpoints.

𝐏𝐚𝐧𝐞𝐥! 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐌𝐞𝐚𝐬𝐮𝐫𝐞𝐬 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: 𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐟𝐨𝐫 𝐑𝐎𝐈. 𝐌𝐨𝐝𝐞𝐫𝐚𝐭𝐨𝐫: Amir Lahav, Advisor for Pharma & MedTech Founder & CEO, SkyMedAI 𝐏𝐚𝐧𝐞𝐥𝐢𝐬𝐭𝐬: -Marissa Dockendorf Executive Director, Head of Digital Clinical Measures, Merck -Stephen Ruhmel Clinical Strategy Lead for Digital Endpoints, Sanofi -Alison Buick, PhD Global Head of Business Development, Cumulus Neuroscience -Ram Miller MD MBA FRCPC Executive Director, Translational Medicine, Neuromuscular Disease, Novartis Institute For Biomedical Research -Ariel Dowling Senior Director, Head of Sensing and Measurement, Data Sciences Institute, Research and Development, Takeda #day3 #healthcareInnovation #summit #conference #dhaiconference #dhai2k24

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

Cumulus Neuroscience is excited to be a Health Tech Challengers 2024 Finalist in the AI Supported Healthcare category! @Health Tech Challengers is a premier platform for discovering and supporting innovative digital health startups that make a difference in the world. Each year, HTC hosts an epic pitch competition for companies who develop disruptive products that will transform the future of health. We’re excited to participate at #HTC2024 in Barcelona on 4-5 December! #AI #HealthTech #MedTech #DigitalHealth

Cumulus Neuroscience is pleased to announce that Alison Buick, PhD, Global Head of Business Development will be discussing the important topic of ROI associated with digital measures on a panel titled “Digital Measures in Clinical Trials: Current Challenges and Opportunities for ROI” at the Digital Health & AI Innovation Summit (DHAI) in Boston, 7-9 October. Thanks to the work of the Digital Medicine Society (DiMe) in collaboration with Tufts University and multiple biopharma industry partners, there is finally published data demonstrating that “despite the need for substantial upfront investment, digital endpoints are yielding substantial expected net present value and ROI to the drug development industry.” Review the publication here: https://lnkd.in/eGinVdwc Let us know if you’re planning to attend #DHAI2024 or if you are in the Boston area and would like to meet for a live demo of our platform! #digitalbiomarkers #digitalmeasures #ai

We are pleased to announce that Tina Sampath has been promoted to Interim CEO. Tina joined Cumulus Neuroscience as CCO in 2023 and was charged with driving growth for the company’s first product, the NeuLogiq™ Neuro-Assessment Platform. Tina assumed the role of Interim CEO this month and is responsible for driving the continued growth of NeuLogiq™ while fundraising and overseeing commercialization planning to support development of the company’s second product AccelADx™.

Alison Buick, PhD, Global Head of Business Development and Brian Murphy, CSO & Co-Founder of Cumulus Neuroscience are looking forward to meeting our industry colleagues at the following Fall 2024 meetings: Neuropsychiatric Drug Development Summit (24-26 September in Boston) Digital Health & AI Innovation Summit (7-9 October in Boston) CNS Summit (10-13 November in Boston) International Pharmaco-EEG Society (IPEG) (21-24 November in Izmir, Turkey) 📆 To schedule a meeting, please contact Alison at 👉 alison@cumulusneuro.com #digitalbiomarkers #NDDS #DHAI2024 #IPEG #CNSSummit2024 Brian Murphy, PhD on Linkedin: https://lnkd.in/ernbTe6d

Our CSO Brian Murphy, PhD recently participated in a panel discussion at the 7th Annual Digital Biomarkers in Clinical Trials Summit titled “Digital Biomarkers in Neuroscience Today.” It was exciting to hear our colleagues in biopharma discuss concrete examples of digital measures adding value and impacting decisions in clinical development. Importantly, digital measures are being used to recruit the right patients and enabling studies with a smaller number of patients, both of which directly decrease costs. #digitalbiomarkers #clinicalstudies Click here to watch the panel discussion: https://lnkd.in/dFkQmBfy Brian Murphy, PhD: https://lnkd.in/ernbTe6d

Cumulus Neuroscience is honored to collaborate with the dedicated team at the Global Brain Health Institute (GBHI). This recent Nature Translational Psychiatry publication demonstrates utility of innovative analytics approaches to explore effects of pharmacological interventions (in this case, ketamine) obtained by low-density, low-burden EEG, maximizing the ability to look at combined information across electrodes. https://lnkd.in/du8-whkT